Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease.

Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D, Talbot K, Harrower T, Walsh J, Chandran S, Hanemann CO, Mills R, Tennant A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):317-327. doi: 10.1080/21678421.2019.1615951. Epub 2019 May 22.

PMID:
31116037
2.

Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology.

Mills SJ, Radon MR, Baird RD, Hanemann CO, Keatley D, Lewis J, Pollock J, Sanghera P, Santarius T, Whitfield G, Zakaria R, Michael D J.

Br J Radiol. 2019 Jun;92(1098):20190059. doi: 10.1259/bjr.20190059. Epub 2019 May 8.

PMID:
30924680
3.

Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.

Ammoun S, Evans DG, Hilton DA, Streeter A, Hayward C, Hanemann CO.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1184-1187. doi: 10.1136/jnnp-2018-319713. Epub 2019 Feb 4. No abstract available.

PMID:
30718294
4.

Molecular and translational advances in meningiomas.

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178.

5.

Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism.

Dunn J, Ferluga S, Sharma V, Futschik M, Hilton DA, Adams CL, Lasonder E, Hanemann CO.

EBioMedicine. 2019 Feb;40:77-91. doi: 10.1016/j.ebiom.2018.12.048. Epub 2018 Dec 26.

6.

Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.

Emmanouil B, Houston R, May A, Ramsden JD, Hanemann CO, Halliday D, Parry A, Mackeith S.

Laryngoscope. 2019 Apr;129(4):974-980. doi: 10.1002/lary.27586. Epub 2018 Nov 19.

PMID:
30456886
7.

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.

Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M, Nagy T, Bignell G, Maura F, Young MD, Berna J, Tubio JMC, McMurran CE, Young AMH, Sanders M, Noorani I, Price SJ, Watts C, Leipnitz E, Kirsch M, Schackert G, Pearson D, Devadass A, Ram Z, Collins VP, Allinson K, Jenkinson MD, Zakaria R, Syed K, Hanemann CO, Dunn J, McDermott MW, Kirollos RW, Vassiliou GS, Esteller M, Behjati S, Brazma A, Santarius T, McDermott U.

Sci Rep. 2018 Sep 10;8(1):13537. doi: 10.1038/s41598-018-31659-0.

8.

Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.

Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T, McDermott CJ, Majeed T, Pinto A, Talbot K, Williams T, Young CA; TONiC study group.

Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.

PMID:
29468643
9.

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J.

Cancer Res. 2017 Sep 15;77(18):5026-5038. doi: 10.1158/0008-5472.CAN-16-2834. Epub 2017 Jul 20.

10.

Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S, Hanemann CO.

Oncogene. 2017 Nov 2;36(44):6132-6142. doi: 10.1038/onc.2017.200. Epub 2017 Jul 10.

PMID:
28692055
11.

Accumulation of autophagosomes confers cytotoxicity.

Button RW, Roberts SL, Willis TL, Hanemann CO, Luo S.

J Biol Chem. 2017 Aug 18;292(33):13599-13614. doi: 10.1074/jbc.M117.782276. Epub 2017 Jul 3.

12.

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG.

Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.

13.

Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.

Bassiri K, Ferluga S, Sharma V, Syed N, Adams CL, Lasonder E, Hanemann CO.

EBioMedicine. 2017 Feb;16:76-86. doi: 10.1016/j.ebiom.2017.01.020. Epub 2017 Jan 18.

14.

A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.

McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Malaspina A, Morrison KE, Orrell RW, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):1-9. doi: 10.1080/21678421.2016.1221433. Epub 2016 Aug 31. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):152.

15.

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8. doi: 10.1212/WNL.0000000000002932.

16.

Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.

Zeissler ML, Eastwood J, McCorry K, Hanemann CO, Zajicek JP, Carroll CB.

Oncotarget. 2016 Jul 19;7(29):46603-46614. doi: 10.18632/oncotarget.10314.

17.

DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.

McDermott CJ, Bradburn MJ, Maguire C, Cooper CL, Baird WO, Baxter SK, Cohen J, Cantrill H, Dixon S, Ackroyd R, Baudouin S, Bentley A, Berrisford R, Bianchi S, Bourke SC, Darlison R, Ealing J, Elliott M, Fitzgerald P, Galloway S, Hamdalla H, Hanemann CO, Hughes P, Imam I, Karat D, Leek R, Maynard N, Orrell RW, Sarela A, Stradling J, Talbot K, Taylor L, Turner M, Simonds AK, Williams T, Wedzicha W, Young C, Shaw PJ.

Health Technol Assess. 2016 Jun;20(45):1-186. doi: 10.3310/hta20450.

18.

Activation of multiple growth factor signalling pathways is frequent in meningiomas.

Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO.

Neuropathology. 2016 Jun;36(3):250-61. doi: 10.1111/neup.12266. Epub 2015 Nov 10.

PMID:
26554033
19.

The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M, Hanemann CO.

Oncogene. 2016 Jun 30;35(26):3443-53. doi: 10.1038/onc.2015.404. Epub 2015 Nov 9.

20.

Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.

Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M.

Am J Med Genet A. 2015 Jan;167A(1):1-10. doi: 10.1002/ajmg.a.36793. Epub 2014 Nov 12.

21.

Artesunate induces necrotic cell death in schwannoma cells.

Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO, Luo S.

Cell Death Dis. 2014 Oct 16;5:e1466. doi: 10.1038/cddis.2014.434.

22.

The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO.

Mol Oncol. 2015 Jan;9(1):236-48. doi: 10.1016/j.molonc.2014.08.005. Epub 2014 Aug 27.

23.

Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.

Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG.

Cancer Cell. 2014 Jul 14;26(1):48-60. doi: 10.1016/j.ccr.2014.05.001.

24.

Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.

Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO, Hornigold R, Axon P, Golding JF.

J Neurol. 2014 May;261(5):963-9. doi: 10.1007/s00415-014-7303-1. Epub 2014 Mar 12.

25.

Schwannomas and their pathogenesis.

Hilton DA, Hanemann CO.

Brain Pathol. 2014 Apr;24(3):205-20. doi: 10.1111/bpa.12125. Epub 2014 Feb 25. Review.

PMID:
24450866
26.

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H.

Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17.

27.

Conclusions and future directions for the REiNS International Collaboration.

Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Plotkin SR.

Neurology. 2013 Nov 19;81(21 Suppl 1):S41-4. doi: 10.1212/01.wnl.0000435748.79908.c5.

28.

Achieving consensus for clinical trials: the REiNS International Collaboration.

Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC.

Neurology. 2013 Nov 19;81(21 Suppl 1):S1-5. doi: 10.1212/01.wnl.0000435743.49414.b6. Review.

29.

Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation.

Rankin J, Short J, Turnpenny P, Castle B, Hanemann CO.

Am J Med Genet A. 2013 Aug;161A(8):2027-9. doi: 10.1002/ajmg.a.36005. Epub 2013 Jun 27.

PMID:
23813970
30.

Management of sialorrhoea in motor neuron disease: a survey of current UK practice.

Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Majeed T, Malaspina A, Morrison K, Orrell RW, Pall H, Pinto A, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):521-7. doi: 10.3109/21678421.2013.790452. Epub 2013 May 7.

PMID:
23647474
31.

Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.

Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schröder JM, Gutmann DH, Giovannini M, Morrison H.

Nat Neurosci. 2013 Apr;16(4):426-33. doi: 10.1038/nn.3348. Epub 2013 Mar 3.

PMID:
23455610
32.

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.

UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, Kelly J, Murphy CL, Al-Chalabi A, Dougherty A, Leigh PN, Wijesekera L, Thornhill M, Ellis CM, O'Hanlon K, Panicker J, Pate L, Ray P, Wyatt L, Young CA, Copeland L, Ealing J, Hamdalla H, Leroi I, Murphy C, O'Keeffe F, Oughton E, Partington L, Paterson P, Rog D, Sathish A, Sexton D, Smith J, Vanek H, Dodds S, Williams TL, Steen IN, Clarke J, Eziefula C, Howard R, Orrell R, Sidle K, Sylvester R, Barrett W, Merritt C, Talbot K, Turner MR, Whatley C, Williams C, Williams J, Cosby C, Hanemann CO, Iman I, Philips C, Timings L, Crawford SE, Hewamadduma C, Hibberd R, Hollinger H, McDermott C, Mils G, Rafiq M, Shaw PJ, Taylor A, Waines E, Walsh T, Addison-Jones R, Birt J, Hare M, Majid T.

Lancet Neurol. 2013 Apr;12(4):339-45. doi: 10.1016/S1474-4422(13)70037-1. Epub 2013 Feb 27. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

33.

Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.

Doddrell RD, Dun XP, Shivane A, Feltri ML, Wrabetz L, Wegner M, Sock E, Hanemann CO, Parkinson DB.

Brain. 2013 Feb;136(Pt 2):549-63. doi: 10.1093/brain/aws353.

34.

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.

Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.

35.

Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas.

Shivane A, Parkinson DB, Ammoun S, Hanemann CO.

Histopathology. 2013 Mar;62(4):651-6. doi: 10.1111/his.12062. Epub 2013 Jan 30.

PMID:
23362975
36.

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.

Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S, Hanemann CO.

Oncogene. 2014 Jan 16;33(3):336-46. doi: 10.1038/onc.2012.587. Epub 2013 Jan 14.

PMID:
23318455
37.

The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.

Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO.

Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20.

PMID:
22821509
38.

Merlin, a multi-suppressor from cell membrane to the nucleus.

Zhou L, Hanemann CO.

FEBS Lett. 2012 May 21;586(10):1403-8. doi: 10.1016/j.febslet.2012.03.016. Epub 2012 Mar 21. Review.

39.

The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state.

Sher I, Hanemann CO, Karplus PA, Bretscher A.

Dev Cell. 2012 Apr 17;22(4):703-5. doi: 10.1016/j.devcel.2012.03.008. No abstract available.

40.
41.

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.

PMID:
22236282
42.

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W 3rd, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M.

Am J Med Genet A. 2012 Jan;158A(1):24-41. doi: 10.1002/ajmg.a.34359. Epub 2011 Dec 2.

43.

Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, Pan D, Stemmer-Rachamimov A, Upadhyaya M, Viskochil D, Wallace MR, Hunter-Schaedle K, Ratner N.

Acta Neuropathol. 2012 Mar;123(3):369-80. doi: 10.1007/s00401-011-0905-0. Epub 2011 Nov 16.

44.

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.

Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM, Hanemann CO.

Oncogene. 2012 Mar 29;31(13):1710-22. doi: 10.1038/onc.2011.357. Epub 2011 Sep 5.

PMID:
21892205
45.

Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.

Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Sci Signal. 2011 Aug 23;4(188):pt6. doi: 10.1126/scisignal.2002314.

PMID:
21878678
46.

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO.

Neuro Oncol. 2011 Jul;13(7):759-66. doi: 10.1093/neuonc/nor056.

47.

Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease.

Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, Hanemann CO.

Neurochem Int. 2011 Aug;59(1):73-80. doi: 10.1016/j.neuint.2011.05.006. Epub 2011 Jun 6.

PMID:
21672570
48.

Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Ammoun S, Hanemann CO.

Nat Rev Neurol. 2011 Jun 7;7(7):392-9. doi: 10.1038/nrneurol.2011.82. Review.

PMID:
21647202
49.

Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis.

Zhang H, Hilton DA, Hanemann CO, Zajicek J.

Brain Pathol. 2011 Sep;21(5):544-57. doi: 10.1111/j.1750-3639.2011.00477.x. Epub 2011 Feb 22.

PMID:
21251115
50.

Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon.

Carroll C, Krolikowski K, Mukonoweshuro W, Jones J, Hanemann CO.

J Neurol. 2010 Dec;257(12):2094-6. doi: 10.1007/s00415-010-5643-z. Epub 2010 Jul 15. No abstract available.

PMID:
20632028

Supplemental Content

Loading ...
Support Center